AffiliationChristie Hospital NHS Trust, Manchester, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractPURPOSE OF REVIEW: Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remains elusive for the majority of patients. Here, we report on progress in evaluating novel targeted therapies for the treatment of this disease. RECENT FINDINGS: Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial in patients with small cell lung cancer. Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ganglioside are also being evaluated. Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib have failed to demonstrate efficacy for this disease. Preliminary data for thalidomide are promising and so results from trials of other antiangiogenics such as bevacizumab and ZD6474 are awaited with interest. SUMMARY: Although the promise of targeted therapy has yet to be realized in patients with small cell lung cancer, the number of agents available for evaluation provides new optimism that progress will be made over the next decades.
CitationSmall cell lung cancer and targeted therapies. 2007, 19 (2):103-8 Curr Opin Oncol
JournalCurrent Opinion in Oncology
- New targets for non-small-cell lung cancer therapy.
- Authors: Alvarez M, Roman E, Santos ES, Raez LE
- Issue date: 2007 Oct
- Multitargeted inhibitors in lung cancer: new clinical data.
- Authors: Bar J, Herbst RS, Onn A
- Issue date: 2008
- Targeted therapies and non-small-cell lung cancer: work in progress?
- Authors: Gridelli C
- Issue date: 2006 Mar
- Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
- Authors: Sangha R, Lara PN Jr, Mack PC, Gandara DR
- Issue date: 2009 Mar
- Antiangiogenic therapy in nonsmall cell lung cancer.
- Authors: Gutierrez M, Giaccone G
- Issue date: 2008 Mar